Compass Pathways Seeks FDA Approval for Psilocybin-Based Depression Treatment

AI-generated NewsSnap summary based on source reporting.
Published: 2026-11-10
Category: health
Source: Drug Discovery and Development
Original source

Compass Pathways has submitted a New Drug Application to the FDA for COMP360, a synthetic psilocybin formulation, targeting treatment-resistant depression. This marks a significant step in exploring psychedelic compounds for mental health, potentially offering a new therapeutic option for a challenging condition. The submission positions Compass Pathways among other companies advancing similar treatments.

Want more?

Open NewsSnap.ai for the full app experience, including audio, personalization, and more news tools.

Open NewsSnap.ai